This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary EGFR Therapeutic Antibody Development
Targeted therapy is increasingly showing promising prospects, especially in the treatment of tumors in companion animals. As a well-established cancer treatment target, EGFR is often overexpressed on several canine and feline cancers and is indicative of a poor outcome. BioVenic provides veterinary EGFR therapeutic antibody development services. Our services include not only antibody preparation using various techniques but also subsequent characterization and engineering modifications. For dual-targeting, we also offer veterinary bispecific therapeutic antibody development services, utilizing emerging technologies to explore new possibilities targeting EGFR and other relevant markers.
Background of EGFR
| Full Name | Epidermal growth factor receptor |
|---|---|
| Aliases | ERBB, ERBB1, ERRP, HER1, mENA, NISBD2, PIG61. |
| Target Profile | EGFR is a transmembrane protein and a member of the ErbB family of tyrosine kinase receptors. Upon binding with specific ligands, such as the epidermal growth factor, a normally functioning EGFR undergoes conformational changes and phosphorylation in its intracellular domain, leading to downstream signal transduction in various pathways. Abnormal activation of EGFR activates key oncogenic signaling pathways, playing a critical role in tumor proliferation, invasion, metastasis, and angiogenesis. |
MoA of EGFR
In a normal body, the binding of specific ligands, such as EGF or TGF-α, to EGFR induces the formation of receptor homodimers or heterodimers, thereby activating the tyrosine kinase domain. This activation leads to the receptor's autophosphorylation, triggering a series of downstream signaling pathways, such as RAS/RAF/MEK/ERK and PI3K/AKT/mTOR. The activation of these pathways is strictly controlled and balanced, crucial for regulating cell growth, differentiation, migration, and apoptosis. In tumor cells, there can be overexpression or mutations of EGFR, increasing the tumor cells' dependence on signaling, and promoting their continuous proliferation. Additionally, the activation of the EGFR signaling pathway can also promote angiogenesis, providing the tumor with necessary nutrients and oxygen, further supporting the tumor's growth and metastasis.
Fig.1 Schematic diagram of EGFR activation and signaling.1
Application in Veterinary Therapeutics
EGFR targeting shows significant potential in cancer treatment for companion animals. In various animal cancers such as canine primary lung cancer, transitional cell carcinoma, mammary carcinoma, intestinal adenocarcinoma, and feline oral/cutaneous squamous cell carcinoma, abnormal expression or mutations of EGFR are closely associated with the worsening of the disease. EGFR therapeutic antibodies can recognize the extracellular domain of the receptor, compete for the ligand binding sites, inhibit EGFR dimerization, and reduce the number of EGFRs on the cell surface. By inhibiting the abnormal activation of the EGFR pathway, these antibodies act to halt the progression of cancer in companion animals and provide therapeutic effects.
Veterinary EGFR Therapeutic Antibody Development Services
EGFR, as a well-researched and mature target, reflects the rapid technological advancements with its diverse drug forms. BioVenic offers comprehensive veterinary EGFR therapeutic antibody development services, encompassing but not limited to antibody preparation using hybridoma technology, single B cell technology, and phage display techniques. Our engineering services, through affinity maturation and antibody modification, enhance the therapeutic efficacy and safety of the antibodies. Furthermore, we focus on the development of species-specific antibodies to improve therapeutic outcomes in different animal species and reduce immunogenicity. The EGFR target continues to foster breakthroughs with the development of bispecific antibodies. BioVenic also provides veterinary bispecific therapeutic antibody development, combining other targets to assist in developing more effective veterinary EGFR therapeutic antibodies.
For more information about our veterinary EGFR therapeutic antibody development services, please click the following link.
Why Choose Us?
We have established multiple platforms to support the rapid preparation of veterinary therapeutic antibodies, offering swift and optimized animal immunization protocols, and providing a complete validation system in the subsequent development process.
Our veterinary therapeutic antibody engineering services extend the antibody's half-life and effectively control the risk of immunogenicity.
The development service for veterinary bispecific therapeutic antibodies aids in achieving precise modulation of dual-target actions for enhanced pharmacological effects.
EGFR, a transmembrane tyrosine kinase, is widely expressed in various animal tissues and plays a significant role in cell growth, differentiation, and survival. BioVenic offers veterinary EGFR therapeutic antibody development services, assisting in exploring the therapeutic potential of the EGFR target in combating canine and feline cancers, opening new possibilities for improving animal treatment outcomes. If you need further information or wish to initiate collaboration, please contact us at any time!
Reference
- Papini, Filippo, et al. "Hype or hope–Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?." Critical Reviews in Oncology/Hematology 166 (2021): 103454.